Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic Disease and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for ACVR1C (ALK7) drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ACVR1C ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. HEK293 Expressed for native glycosylation. |
View ACVR1C Products |
| Gene Delivery | ACVR1C Lentivirus Premade Particles Full-length ORF for stable cell line construction. Internalization and signaling assays. |
View ACVR1C Products |
| Benchmark Ab | Anti-ACVR1C Reference Antibody Recombinant positive control for binding specificity validation. |
View ACVR1C Products |
| Validator | ACVR1C siRNA Set (3 unique sequences) For knockdown verification and assay specificity controls. |
View ACVR1C Products |
| Related Target: ACVR1B | ACVR1B (ALK4) ECD-Fc Protein Subfamily selectivity counter-screening. Critical for avoiding off-target Activin A signaling. |
View ACVR1B Products |
| Related Target: ACVR2A | ACVR2A ECD-Fc Protein Type II receptor for heteromeric complex formation studies. |
View ACVR2A Products |
| Related Target: INHBB | Activin B (INHBB) Recombinant Protein Primary ligand for ACVR1C binding and competition assays. |
View INHBB Products |
| Related Target: NODAL | NODAL Recombinant Protein Alternative ligand for ACVR1C pathway activation (via Cripto co-receptor). |
View NODAL Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily Selectivity (ACVR1C vs ACVR1B/ALK4) | ACVR1C and ACVR1B ECD proteins with >95% purity, sequence verified by Mass Spec. Ortholog proteins available for strict counter-screening. |
| Cross-species Preclinical Evaluation | Human/Mouse/Cyno ortholog proteins expressed in HEK293. Conserved glycosylation patterns for accurate binding kinetics. |
| Ligand Competition Binding (Activin B vs Nodal) | High-purity ACVR1C ECD-Fc with theoretical MW confirmed. Suitable for SPR/BLI affinity ranking. |
| False Positives in Functional Assays | Sequence-verified siRNA set included for target-specificity verification in SMAD2/3 reporter assays. |
| Cell-based Signaling Validation | Lentivirus particles for stable ACVR1C overexpression. Preserves native conformation for physiologic activation studies. |
Live ACVR1C R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ACVR1C (ALK7) therapeutics is intensifying, with major players shifting focus from broad-spectrum activin inhibitors to ACVR1C-selective decoys. As first-generation pan-activin blockers face safety limitations (cardiac fibrosis concerns), the next wave of R&D is targeting subfamily-specific ligand traps and oral kinase inhibitors to preserve metabolic benefits while minimizing off-tissue toxicity. Preclinical evidence links receptor modulation to adipose tissue browning, insulin secretion, and energy homeostasis, positioning ACVR1C as a next-wave target beyond the well-characterized ActRIIB axis. The convergence of obesity and oncology pipelines is creating unique demand for dual-mechanism assays that can distinguish adipocyte browning signals from tumor microenvironment effects.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Soluble Receptor Decoy (Fc-fusion) | Novo Nordisk, Roche, Scholar Rock | Obesity, Type 2 Diabetes, NASH | Ligand Binding (Activin B sequestration) with ACVR1C ECD-Fc. Species cross-reactivity panel required. |
| Monoclonal Antibody (Anti-ACVR1C) | Regeneron, Biogen | Metabolic Syndrome, Cachexia | Blocking assay vs ACVR1B selectivity. Need human/cyno/mouse ortholog trio for lead selection. |
| Small Molecule Kinase Inhibitor | Academic Consortia, Emerging Biotech | Solid Tumors (context-dependent) | Intracellular domain active protein. Kinase assay with mutant variants for resistance profiling. |
| Bispecific (Anti-ACVR1C/ACVR1B) | Roche, Novartis | Fibrotic Diseases | Heterodimer validation. Dual-target binding confirmation using both receptor ECDs. |
Note: ACVR1C functional domains (GS domain and Protein kinase domain) and key mutations (rs56188432, rs34742924, lung squamous cell carcinoma somatic mutation) are cataloged in UniProt Q8NER5 and are compatible with TarMart's assay design for mutant screening and selectivity profiling.